What Patients Should Know About Ozempic and Gastroparesis

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Legal Guidance

If you're experiencing persistent nausea, vomiting, or abdominal pain while taking Ozempic, you may be concerned about gastroparesis—a condition where stomach emptying is delayed. This page provides the medical facts on diagnosis and follow-up, building on a long tradition of translating clinical research into clear patient guidance.

Medical and Risk Considerations for Virginia Patients

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can significantly impair quality of life and nutritional status. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes. Its pharmacology includes slowing gastric emptying as part of its mechanism to reduce postprandial glucose excursions. This effect, while therapeutic for glycemic control, can also contribute to gastrointestinal adverse reactions. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: placebo 15.3%, Ozempic 0.5 mg 32.7%, and Ozempic 1 mg 36.4% (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) versus Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions reported with Ozempic at frequencies below 5% include dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal symptoms, which may overlap with the clinical presentation of gastroparesis.

Mechanistic Link and Warning Adequacy

The mechanistic pathway linking Ozempic to gastroparesis involves the drug's effect on gastric motility. GLP-1 receptor agonists like semaglutide delay gastric emptying by inhibiting antral contractions and stimulating pyloric tone. In susceptible individuals, this pharmacologic effect may become pathologic, leading to symptomatic gastroparesis. The timeline between exposure and documented harm can vary. Some patients develop symptoms during dose escalation, while others may experience delayed onset after months of treatment. The label notes that the majority of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but persistent symptoms may indicate progression to gastroparesis. Regarding the adequacy of warnings, the Ozempic prescribing information includes gastrointestinal adverse reactions in the label but does not specifically list gastroparesis as a warning or precaution. The label does include a warning for serious hypersensitivity reactions such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but gastroparesis is not explicitly mentioned. This omission may be relevant for patients who develop severe or persistent gastrointestinal symptoms that meet diagnostic criteria for gastroparesis. The adequacy of warnings is a key consideration in legal claims, as patients and their attorneys may argue that the manufacturer failed to adequately communicate the risk of this specific condition.

Statute of Limitations and Legal Considerations in Virginia

For Virginia patients considering legal action, the statute of limitations for product liability claims involving Ozempic and gastroparesis is generally two years from the date the injury was discovered or reasonably should have been discovered. Virginia Code Section 8.01-243(A) sets this limitation for personal injury actions. However, there may be nuances depending on whether the claim is based on negligence, strict liability, or failure to warn. It is essential for affected patients to consult with an attorney experienced in pharmaceutical litigation to determine the applicable deadline based on their specific circumstances. Attorney-related considerations for affected patients include documenting the timeline of Ozempic use, onset of gastrointestinal symptoms, medical diagnosis of gastroparesis, and any communications with healthcare providers about the drug's side effects. Patients should retain all medical records, prescription histories, and packaging inserts. The link between exposure and harm is supported by the pharmacologic mechanism and clinical trial data showing increased gastrointestinal adverse reactions with Ozempic use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, establishing causation may require expert testimony to differentiate drug-induced gastroparesis from other causes, such as diabetes itself, which is a known risk factor for gastroparesis. In summary, the evidence indicates that Ozempic is associated with gastrointestinal adverse reactions that can include symptoms consistent with gastroparesis. The drug's label does not specifically warn about gastroparesis, which may be relevant for legal claims. Virginia patients should be aware of the two-year statute of limitations and seek prompt legal advice to preserve their rights.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Virginia?

In Virginia, the statute of limitations for product liability claims involving Ozempic and gastroparesis is generally two years from the date the injury was discovered or reasonably should have been discovered, as per Virginia Code Section 8.01-243(A). However, nuances may apply based on the legal theory (negligence, strict liability, failure to warn). It is crucial to consult an attorney promptly to preserve your rights.

Does Ozempic's label warn about gastroparesis?

The Ozempic prescribing information includes gastrointestinal adverse reactions but does not specifically list gastroparesis as a warning or precaution. The label does warn about serious hypersensitivity reactions such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This omission may be relevant for legal claims regarding failure to warn.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.